Thyroid cancer surgery is the cornerstone of definitive oncologic management for thyroid malignancies. The primary goals are complete tumor removal, minimizing risk of local recurrence, facilitating postoperative radioiodine therapy when indicated, and permitting accurate pathological staging. Performed within endocrine surgery and head and neck surgical oncology, the procedure targets malignant transformation within thyroid follicular or parafollicular C-cells.

Thyroid cancer surgery is conducted under general anesthesia. The surgeon makes a horizontal incision in a lower neck skin crease (collar incision). The strap muscles are gently separated to expose the thyroid gland. The surgeon carefully identifies and preserves the parathyroid glands and the recurrent laryngeal nerves, often utilizing intraoperative nerve monitoring. The blood vessels supplying the target thyroid lobe or the entire gland are divided close to the thyroid capsule. The thyroid tissue is removed along with any involved central or lateral compartment lymph nodes. The surgical bed is inspected for bleeding, and the wound is closed in anatomical layers using absorbable sutures.

Evidence indicates that appropriate thyroid cancer surgery provides complete local tumor control and excellent overall survival. According to American Thyroid Association guidelines, surgical resection combined with risk-adapted adjuvant therapy achieves 10-year overall survival rates exceeding 90% to 95% for low- and intermediate-risk differentiated thyroid cancers. Surgery also enables precise pathological staging and risk stratification for ongoing disease monitoring.

Initial physical recovery requires 1 to 2 weeks, during which incision healing, pain management, and calcium level monitoring take place. Most patients resume light activities within 3 to 5 days and full physical activity within 3 weeks. Long-term recovery involves life-long thyroid hormone replacement therapy for total thyroidectomy patients, with biochemical and ultrasound surveillance conducted at 3 to 6 month intervals initially.

Thyroid cancer surgery treats several types of thyroid carcinoma, including papillary thyroid carcinoma, follicular thyroid carcinoma, Hürthle cell carcinoma, medullary thyroid carcinoma, and select resectable cases of anaplastic thyroid carcinoma. It is also indicated for high-risk indeterminate thyroid nodules (Bethesda categories IV, V, and VI) and recurrent thyroid malignancies.

Preoperative preparation includes a physical exam, high-resolution neck ultrasound, and fine-needle aspiration biopsy. Vocal cord mobility is assessed via flexible laryngoscopy. Blood tests measure thyroid-stimulating hormone (TSH), calcium, and baseline thyroglobulin or calcitonin levels. Patients must fast for 8 hours prior to surgery and temporarily discontinue medications that increase bleeding risk, such as antiplatelet agents or anticoagulants, under medical supervision.

Complications include temporary hypocalcemia due to parathyroid stunning (10-25%), permanent hypoparathyroidism (<2%), temporary recurrent laryngeal nerve palsy causing hoarseness (2-5%), permanent nerve injury causing vocal cord paralysis (<1%), postoperative hematoma requiring evacuation (<1%), wound infection (<1%), and keloid incision scarring.

The patient journey begins with diagnostic evaluation, including ultrasound-guided fine-needle aspiration biopsy and biochemical testing. Preoperatively, patients undergo voice assessment and surgical planning. On the day of surgery, general anesthesia is administered, and resection is performed with intraoperative nerve monitoring. Following a 24-to-48-hour hospital stay, patients begin recovery, hormone replacement titration, and long-term surveillance monitoring.